Patents by Inventor Qingyi YANG

Qingyi YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240182468
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.
    Type: Application
    Filed: October 11, 2023
    Publication date: June 6, 2024
    Inventors: GARY ERIK ASPNES, CHRISTOPHER RYAN BUTLER, MATTHEW FRANK PAUL CALABRESE, KIMBERLY O'KEEFE CAMERON, JOHN MARION CURTO, MICHAEL ERIC GREEN, XINJUN HOU, SHENPING LIU, CHRISTOPHER LEE MCCLENDON, JOHN CHARLES MURRAY, ADVAITA PANCHAGNULA, COLIN RICHARD ROSE, KYLE THOMAS TARANTINO, MEIHUA MIKE TU, RAYOMAND JAL UNWALLA, JOSEPH SCOTT WARMUS, JUN XIAO, QINGYI YANG, LEI ZHANG
  • Publication number: 20240102955
    Abstract: A non-invasive time domain reflection probe calibration method includes: using different volume ratio of ethanol and deionized water mixed solution to calculate a test target's medium weight coefficient and waveguide length of the non-invasive time domain reflection probes; using different concentrations of NaCl solutions to calibrate a waveguide geometric dimensioning of the non-invasive time domain reflection probes; preparing compacted soil samples with known different moisture contents and densities, and calibrating a correlation parameter of compacted soil samples' dielectric constant and conductivity with moisture content and density. The method not only determines the sensitivity of the test target medium of the non-invasive time domain reflection probes, but also obtains the waveguide length and geometric dimensioning of the probe, and realizes an accurate test of moisture content and density of the soil.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 28, 2024
    Applicants: China Jikan Research Institute Of Engineering Investigations And Design, Co.,Ltd, Xi'an Jiaotong University
    Inventors: Jie CAO, Yonglin YANG, Zaixin WAN, Peng GAO, Qingyi MU, Dongjing WANG, Yuanqiang ZHOU, Zhi LIU, Long ZHANG, Hui LI, Jian CHEN, Teng YANG, Lei RAN, Jiao LIN, Xiao DONG, Shuai LIU, Weiwei ZHAO
  • Publication number: 20230384481
    Abstract: Systems and methods which provide single nanostructure-integrated metalens configurations implementing light focusing functionality are described. A single nanostructure-integrated metalens may comprise an optical substrate having a preconfigured mapping of integrated nanostructures providing metasurfaces for modulating the behaviors of electromagnetic waves to implement a thin, flat lens. A period distance for the nanostructures, a height of the nanostructures, and a quantization for lateral sizes of the nanostructures may be selected for a particular single nanostructure-integrated metalens configuration. One or more phase maps configured for light focusing may be computed with respect to one or more design wavelengths selected for focusing. The consolidated phase retardation requirements of the one ore more phase maps may be satisfied by a preconfigured mapping which defines the phase distribution for the nanostructures of a single nanostructure-integrated metalens implementation.
    Type: Application
    Filed: August 11, 2023
    Publication date: November 30, 2023
    Inventors: Yunhe Lai, Ying Suet Lau, Qingyi Yang, Jinbo Jiang
  • Publication number: 20230375747
    Abstract: Systems and methods which provide single nanostructure-integrated metalens configurations implementing projector and light shaper functionality are described. A single nanostructure-integrated metalens may comprise an optical substrate having a preconfigured mapping of integrated nanostructures providing metasurfaces for modulating the behaviors of electromagnetic waves to implement a thin, flat lens. A period distance for the nanostructures, a height of the nanostructures, and a quantization for lateral sizes of the nanostructures may be selected for a particular single nanostructure-integrated metalens configuration. A first phase map may be computed with respect to structured light generation and a second phase map may be computed with respect to light collimation, wherein fusion of these phase maps may be used to define a preconfigured mapping for the nanostructures of a single nanostructure-integrated metalens implementation.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 23, 2023
    Inventors: Yunhe Lai, Haoyuan Bai, Qingyi Yang, Jinbo Jiang
  • Publication number: 20230339930
    Abstract: The invention relates to compounds of Formula I wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Application
    Filed: July 7, 2021
    Publication date: October 26, 2023
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Qingyi Yang
  • Patent number: 11696509
    Abstract: The present disclosure provides a flexible electric generator and methods for fabricating the same. The flexible electric generator comprises a flexible triboelectric layer covering the electrode layer of a flexible piezoelectric generator that enhances output power by combining piezoelectric effect and triboelectric effect. The reliability of the flexible electric generator under bending is also improved due to the presence of the flexible triboelectric layer. The fabrication methods of the disclosed flexible electric generators are simple, thereby enabling large-scale manufacturing.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 4, 2023
    Assignee: Nano and Advanced Materials Institute Limited
    Inventors: Han Wang, Qingyi Yang, Jianjun Song, Kwok Keung Paul Ho, Jifan Li
  • Publication number: 20230192654
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: October 19, 2022
    Publication date: June 22, 2023
    Inventors: Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Michael Aaron Brodney, Laura Ann McAllister, Qingyi Yang, Christopher John Helal, Damien Webb
  • Publication number: 20230174532
    Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.
    Type: Application
    Filed: January 31, 2023
    Publication date: June 8, 2023
    Applicant: Pfizer Inc.
    Inventors: Christopher Ryan BUTLER, Michelle Renee GARNSEY, Kevin Alexander OGILVIE, Jana POLIVKOVA, Matthew Forrest SAMMONS, Aaron Christopher SMITH, Qingyi Yang
  • Patent number: 11643412
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • Publication number: 20230120254
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: September 14, 2022
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
  • Publication number: 20230090990
    Abstract: A red-luminescent long-afterglow phosphor, represented by MgxZnyGezO3: aMn2+, bEu3+, cR3+. The phosphor is a kind of oxide compound based white powder. The phosphor powder synthesis process is environmentally friendly, no sintering-assisted gas required and no harmful gas generated during or after sintering. The phosphor powder can be excited by UV and is chemically stable.
    Type: Application
    Filed: August 25, 2022
    Publication date: March 23, 2023
    Inventors: Han WANG, Qingyi YANG, Jifan LI
  • Publication number: 20230019853
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Application
    Filed: June 8, 2021
    Publication date: January 19, 2023
    Applicant: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • Patent number: 11541034
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 3, 2023
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Patent number: 11524954
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: December 13, 2022
    Assignee: Pfizer Inc.
    Inventors: Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Michael Aaron Brodney, Laura Ann McAllister, Qingyi Yang, Christopher John Helal, Damien Webb
  • Patent number: 11452711
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: September 27, 2022
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
  • Publication number: 20220257563
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 18, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
  • Patent number: 11351149
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 7, 2022
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Publication number: 20220142976
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 12, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Publication number: 20220062232
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: August 5, 2021
    Publication date: March 3, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Patent number: 11203594
    Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: December 21, 2021
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Douglas Carl Behenna, Kimberly O. Cameron, Ping Chen, John M. Curto, Kevin Daniel Freeman-Cook, Mehran Jalaie, Robert Steven Kania, Yajing Lian, Sajiv Krishnan Nair, Cynthia Louise Palmer, Martin Youngjin Pettersson, Eugene Yuanjin Rui, Matthew Sammons, Qingyi Yang, Liying Zhang